Tag Archive for: danegaptide

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, […]